Noriyuki Masuda
Overview
Explore the profile of Noriyuki Masuda including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
143
Citations
1303
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Masuda N, Ohe Y, Gemma A, Kusumoto M, Yamada I, Ishii T, et al.
Cancer Sci
. 2019 Feb;
110(4):1401-1407.
PMID: 30776174
We conducted a large-scale surveillance study as a post-marketing commitment to investigate the safety and effectiveness of alectinib in patients with ALK-positive non-small-cell lung cancer (NSCLC) in Japan. Patients receiving...
12.
Sakamoto K, Noguchi Y, Imazumi K, Ueshima K, Ohtake A, Takeda M, et al.
Eur J Pharmacol
. 2019 Jan;
847:83-90.
PMID: 30658116
Current pharmacotherapies for voiding dysfunctions are in need of improvement. Lysophosphatidic acid (LPA) is a phospholipid that contracts the urethra by activating type 1 LPA receptors (LPA). However, the role...
13.
Gemma A, Kusumoto M, Kurihara Y, Masuda N, Banno S, Endo Y, et al.
J Thorac Oncol
. 2018 Dec;
14(4):672-682.
PMID: 30521972
Introduction: The study objective was to determine the incidence and characteristics of drug-induced interstitial lung disease (ILD) associated with an orally available small-molecule tyrosine kinase inhibitor, crizotinib, in a real-world...
14.
Sakamoto K, Noguchi Y, Ueshima K, Yamakuni H, Ohtake A, Sato S, et al.
J Pharmacol Exp Ther
. 2018 Jun;
366(2):390-396.
PMID: 29884626
Current pharmacotherapies for lower urinary tract symptoms associated with benign prostate hyperplasia (LUTS/BPH) are in need of improvement. Lysophosphatidic acid (LPA) is a phospholipid with various biologic functions. However, its...
15.
Nakahara Y, Fukui T, Shirasawa M, Harada S, Kusuhara S, Takakura A, et al.
Intern Med
. 2018 Jun;
57(21):3149-3152.
PMID: 29877291
We herein report the case of a 52-year-old man with stage IV lung adenocarcinoma. The patient was negative for epidermal growth factor receptor (EGFR) mutations and echinoderm microtubule-associated protein-like 4...
16.
Niwa H, Nakahara Y, Sasaki J, Masuda N
BMJ Case Rep
. 2018 Jun;
2018.
PMID: 29866661
Most patients with non-small cell lung cancer with common epidermal growth factor receptor (EGFR) mutations respond dramatically to EGFR tyrosine kinase inhibitors (TKIs), but data are limited on the response...
17.
Niwa H, Otani S, Nakada N, Sasaki J, Saka H, Masuda N
Respir Med Case Rep
. 2018 May;
23:131-135.
PMID: 29719799
Carcinosarcoma is a rare histological type of non-small cell carcinoma (NSCLC), and its prognosis has been reported to be worse compared with other NSCLCs. Nanoparticle albumin-bound paclitaxel (nab-PTX) + carboplatin...
18.
Ikeda S, Kato T, Ogura T, Sekine A, Oda T, Masuda N, et al.
BMC Cancer
. 2018 Mar;
18(1):241.
PMID: 29499653
Background: Preclinical studies have demonstrated that docetaxel and bevacizumab may act synergistically by decreasing endothelial cell proliferation and preventing circulating endothelial progenitor mobilization. The objective of this study was to...
19.
Matsumoto T, Nagashio R, Ryuge S, Igawa S, Kobayashi M, Fukuda E, et al.
Pathol Int
. 2018 Feb;
68(4):232-240.
PMID: 29431238
We established the KU-Lu-8 monoclonal antibody (MoAb) using a lung cancer cell line as an antigen and a random immunization method. The KU-Lu-8 MoAb recognizes basigin (BSG), which is a...
20.
Katono K, Sato Y, Kobayashi M, Nagashio R, Ryuge S, Igawa S, et al.
Onco Targets Ther
. 2017 Nov;
10:5273-5279.
PMID: 29138580
Purpose: Although cisplatin-based adjuvant chemotherapy improves the survival of patients with resected non-small-cell lung cancer, not all patients show a survival benefit, and some patients experience severe toxicity. Therefore, identifying...